6533b85bfe1ef96bd12bb608

RESEARCH PRODUCT

Hepatitis C-related cirrhosis. Current status.

Marina BerenguerCarmen VinaixaIsabel Conde

subject

Liver Cirrhosismedicine.medical_specialtyCirrhosisLiver fibrosisGlobal HealthGastroenterologyAntiviral AgentsVirus03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansLiver decompensationDisease burdenbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationSpain030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy Combinationbusiness

description

Chronic hepatitis C virus (HCV) infection affects around 150 million people. It is a leading cause of liver related morbidity and mortality through its predisposition to liver fibrosis, cirrhosis and end-stage liver complications. New treatments based on direct-acting antivirals have opened a new era in the management of HCV cirrhosis. They allow for HCV eradication without substantial side effects in almost all cirrhotic patients, reducing the risk of hepatocellular carcinoma, liver decompensation and mortality. This review provides an update on HCV cirrhosis. The paper focuses on the disease burden and major progresses in the diagnosis, follow-up and treatment of this patient subgroup.

yearjournalcountryeditionlanguage
2016-07-29Medicina clinica
10.1016/j.medcli.2016.09.019https://pubmed.ncbi.nlm.nih.gov/27855947